The abstract is titled, "Recombinant human intestinal trefoil factor(rhITF) oral spray for prophylaxis of chemotherapy-induced oral mucositis."

The GI Company's lead Phase II clinical candidate, Intestinal TrefoilFactor (ITF), is an endogenous protein in development for the treatment oforal mucositis, a common, debilitating complication resulting fromhigh-dose chemotherapy and / or radiotherapy. The GI Company has retainedBurrill & Company to assist in the selection of a transaction partner forits clinical programs.

About Intestinal Trefoil Factor

Intestinal Trefoil Factor is an endogenous protein found primarily onmucosal surfaces throughout the gastrointestinal tract, including themouth, esophagus and intestines, as well as in other tissues such as theeye and lungs. The protein is known to promote mucosal restitution andrepair and is therefore being developed as a therapeutic. ITF mucositistherapy is designed to alleviate damage to the soft tissues of the oralcavity by providing ITF to the cells of the mouth and throat using aproprietary buccal (oral) delivery system. This therapeutic target isbacked by proven biology and compelling efficacy data on ITF in numerous invivo models of mucosal damage.

About Oral Mucositis

Oral mucositis, also called stomatitis, is a common, serious complicationresulting from high-dose chemotherapy and / or radiotherapy. Thesecytotoxic therapies are used to kill cancer cells, but they alsoindiscriminately kill other fast-growing cells such as those lining theinside of the mouth and throat. Oral mucositis is an inflammation of themucosa of the mouth which ranges from redness to severe ulcerations on theinner cheek, tongue and lips. These debilitating oral sores furtherdiminish quality of life by preventing patients from eating, drinking, ortalking for weeks at a time. These conditions can reappear after everycourse of treatment. In addition to extremely painful open oral sores,patients with oral mucositis typically have diminished immunity resultingfrom chemotherapy and / or radiotherapy and are prone to seriouslife-threatening opportunistic infections. Currently, there is noeffective treatment approved to prevent oral mucositis or shorten itsduration. This condition can affect as many as 80 percent of bone marrow /blood stem cell transplant patients and 40 percent of chemotherapy /radiotherapy patients. This market represents a $1B annual marketopportunity in the U.S. alone.

About MASCC

The Multinational Association of Supportive Care in Cancer (MASCC) is aninternational, multidisciplinary organization with members representingover sixty (60) countries and five continents. Founded in 1990, MASCC isdedicated to research and education in all aspects of supportive care forpatients with cancer, regardless of the stage of their disease. In 1998MASCC joined forces with the International Society of Oral Oncology (ISOO),an organization that addresses the management of complications arising inoral tissues secondary to cancer and its treatment. For more information,please visit http://www.mascc.org/.

About The GI Company, Inc.

The GI Company is a clinical-stage biotechnology company highly specializedat developing drugs to treat gastrointestinal and related diseases. Thecompany's lead clinical candidate is Intestinal Trefoil Factor (ITF) whichis being developed for the treatment of oral mucositis. The GI Companyalso has pre-clinical development projects in enteritis / proctitis,inflammatory bowel disease, erosive gastroesophageal reflux disease, pepticulcer disease and gastrointestinal motility disorders, as well as clinicalprograms in erosive gastritis (NSAID induced), ulcerative colitis andcorneal wound healing. The company is funded through a private equityfinancing consortium and has raised over $20M to date. For moreinformation, please visit www.thegicompany.com.